期刊文献+

5例氨磷汀相关低钙性手足搐搦的分析 被引量:4

下载PDF
导出
摘要 目的分析氨磷汀相关低钙性手足搐搦的临床特点及预防方法。方法应用氨磷汀发生低钙性手足搐搦的患者共5例,氨磷汀按500mg~600mg/m2于化疗前30min,静脉滴注15min,手足搐搦发生于用氨磷汀6h以后,大部分在8~10h之间,发作时意识清楚,生命体征正常,立即监测血离子及血糖至正常。结果均可排除低血糖及颅脑疾患,发作时同时均伴有轻度的低钾血症,发作时血钙浓度均≤2mmol/l,钙剂治疗有效,血钙升至2.0mmol/l以上症状不再出现,低钙血症持续2d恢复,低钾血症在第2天恢复。发生率约0.3%。结论氨磷汀可引起伴手足搐搦的低钙血症,为可逆性,可预防。
出处 《中国现代药物应用》 2010年第1期171-172,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献1

二级参考文献7

  • 1Schuchter LM,Luginbuhl WE,Meropol NJ.The current status oft oxicity protectantsin cancertherapy[].Seminars in Oncology.1992
  • 2Turrisi AT,Giover DJ,Hurwitz S,et al.721[].Cancer Treatment Reports.1986
  • 3Kligerman MM,Turrisi AT 3d,Urtasum RC,et al.721 before protracted fractionted radiation therapy[].International Journal of Radiation Biology.1988
  • 4Turrisi AT,Glover DJ,Hurwitz S,et al.721[].Cancer Treatment Reports.1986
  • 5Adamson PC,Balis FM,Belasco JE,et al.721) and mlphalan in children with refractory cancer[].Cancer Research.1995
  • 6Lynn M,Schucher.Guidelines for the Administration of Amifostine[].Seminn Oncol.1996
  • 7Wadler S,Haynes H,Beitler JJ,et al.Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy[].Journal of Clinical Oncology.1993

共引文献10

同被引文献34

  • 1东星月,李晓冰,杜红光,汪运山.新型细胞保护剂——氨磷汀[J].肿瘤防治杂志,2004,11(8):888-890. 被引量:11
  • 2郭晔,刘晔,许立功,郭慕依.氨磷汀对顺铂肾毒性损伤的保护作用及其机制的研究[J].中华肿瘤杂志,2006,28(1):8-12. 被引量:19
  • 3毛建芬.化疗前使用阿米福汀的观察与护理[J].护理与康复,2007,6(1):61-62. 被引量:7
  • 4俞伟,马林.阿米福汀的临床研究进展[J].中华放射医学与防护杂志,2007,27(1):101-103. 被引量:6
  • 5Karnafaky D A, Burchenal J H. The clinical eralua- tion of chemother apentic agents in cancer [M]// Macelod C M. Evaluation of chemotherapeutic agemts. New York: Columbia University Press, 1994:191-205.
  • 6Bohuslavizki K H, Klutmann S, Bleckmann C, et al. Salivary gland protection by amifostine in high-dose radioiodine therapy of differen-tiated thyroid cancer [J]. Strahlenther Onkol, 1999,75 (2): 57-59.
  • 7Bourhis J , De Crevoisier R , Abdulkarin B , et al .Arandomized study of very accelerated radiotherapy with and without amifostine in head and neck squa- mous cell carcinoma [J]. Int J Radiat Oncol Biol Phys,2000,45(5):1 105-1 108.
  • 8Buntael J, Kutmer K, Frohlich D, et al. Sclective cy- toprotection with amifostine in concurrent ra- diochemotherapy for head and neck cancer [J]. Ann Oncol, 1998,9 (5) : 471-473.
  • 9Gronberg BH,Bremnes RM,Flotten O,et al.Phase III study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer[J] .Clin Oncol,2009,27(19):3217-3224.
  • 10Kouvaris JR,Kouloulias VE,Vlahos LJ.Amifostine:the first selective-target and broad-spectrum radioprotector[J] .Oncologist,2007,12(6):738-747.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部